Kairos
Back to jobs

Senior Scientist I, Cellular Neuroscience and Translational Pharmacology

On-site
Lexeo TherapeuticsNew York, NY, US21 hours agoWebsite
Fresh
Full-time
Senior
Pre-clinical

Compensation

$143,500-$160,000/yr
Apply
Share

Description

Role Summary 

We are seeking a highly collaborative, hands-on Senior Scientist I to help establish a preclinical neuroscience laboratory supporting small-molecule and protein therapeutics. The immediate priorities are rapid cellular profiling and lead selection for an advanced small-molecule enzyme program, and leadership of cellular development for a transferrin-based protein replacement project. The role will also build fit-for-purpose human neuronal models, laboratory workflows, and external partnerships. 

Location 

We welcome applications from candidates located across the Northeast and Mid-Atlantic. 

Primary Responsibilities

  • Lead a rapid, tiered cellular assay strategy for small-molecule lead optimization, including target engagement, pharmacodynamics, concentration-response, duration, selectivity, neuronal phenotype, stress, and tolerability
  • Lead cellular development of a transferrin-based protein replacement project by establishing quantitative assays for construct uptake, internalization, intracellular trafficking, protein abundance and integrity, mitochondrial response, and disease-relevant phenotypic rescue
  • Use orthogonal methods to distinguish surface-bound, internalized, degraded, and functionally delivered protein; compare constructs and define advancement criteria
  • Establish fit-for-purpose neuronal culture models, including iPSC-derived neurons or glia where they add decision value, with appropriate banking and quality control
  • Define assay controls, acceptance criteria, reproducibility standards, analysis plans, SOPs, sample tracking, and electronic documentation
  • Translate data into concise recommendations to advance, modify, or discontinue assets
  • Partner across protein engineering, chemistry, bioanalysis, DMPK, pathology, computational biology, and in vivo pharmacology; scientifically manage CROs and assay transfers
  • Mentor junior scientists and build workflows that are reproducible across operators. Future scope may include ASO screening in partnership with external experts 
  • Required Skills and Qualifications

  • PhD in pharmacology, neuroscience, molecular biology, chemical biology, cell biology, or a related discipline, plus 3 to 6 years of biotechnology or pharmaceutical industry experience
  • Demonstrated experience in cellular pharmacology, assay development, and iterative drug discovery or lead optimization
  • Hands-on experience with neuronal cell culture models, preferably human iPSC-derived neurons or glia
  • Expertise in concentration-response, time-course, target-engagement, pharmacodynamic, quantitative data-analysis, and troubleshooting studies
  • Concrete examples of scientific ownership in which an assay, platform, or data package influenced a program decision
  • Excellent communication skills and willingness to maintain a substantial hands-on laboratory presence 
  • Preferred Skills and Qualifications

  • Enzyme biology, epigenetics, or transcriptional pharmacology; therapeutic proteins or targeted-delivery constructs; cellular uptake, trafficking, or protein quantification; mitochondrial functional assays; high-content imaging or neuronal functional assays; transferrin receptor biology, BBB transport, or biodistribution; laboratory start-up, assay transfer, or CRO management
  • Exposure to ASO screening or RNA pharmacology is beneficial 
  • About LEXEO 

    Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need. 

    LEXEO Therapeutics is an EEO employer committed to an exciting, diverse, and enriching work environment. 

    Posted
    Oct 13, 2026
    Last seen
    Oct 13, 2026
    First seen
    Oct 13, 2026

    Similar roles

    Browse more AI jobs